Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
One Percent Rule Checklist For Safer Forex Trading Risk 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
TORONTO, April 19, 2017 -- NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ), the leading provider of proven comprehensive fluorescence imaging solutions that improve clinical outcomes and reduce healthcare costs in minimally invasive and open surgeries, today announced that it will release financial results for the first quarter of 2017 after the close of trading on Wednesday, May 3, 2017. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing 877-407-8031 (within Canada and the U.S.) or 201-689-8031 (outside Canada and the U.S.). A live and archived webcast of the event will be available on the “Investor Relations” section of the Company’s website at: www.novadaq.com.
A replay of the call will be available for 48 hours by calling (877) 481-4010 (within Canada and the U.S.) or (919) 882-2331 (outside Canada and the U.S.), using Conference ID:10307.
About NOVADAQ Technologies Inc.
NOVADAQ’s global mission is to enable physicians with point-of-care imaging solutions that provide real-time clinically significant and actionable information to improve care quality and lower healthcare costs. Using NOVADAQ’s SPY fluorescence imaging technology, physicians can personalize therapy and achieve optimal results through the precise visualization of blood flow in vessels, micro-vessels, tissue perfusion and critical anatomical structures during the course of treatment. SPY technology enables the delivery of personalized therapies and the achievement of the optimal results for each individual patient. More than 240 peer-reviewed publications demonstrate that the use of SPY technology will reduce post-procedure complication rates and the cost of care for a broad variety of surgical treatments for cancer, cardiovascular diseases and other conditions, helping to ensure that patients benefit from the very best possible treatment and outcome.
SPY Imaging Systems are U.S. Food and Drug Administration 510(k) cleared, Health Canada licensed, CE Marked and registered worldwide for use in multiple surgical specialties and medical applications. The endoscopic version of SPY technology, known as PINPOINT, combines the fluorescence imaging capabilities of SPY with the high definition visible light visualization to establish a new standard in the quality and performance of minimally invasive surgery. NOVADAQ’s LUNA System is used to visualize blood flow and tissue perfusion while treating patients with atherosclerotic cardiovascular disease that impairs blood flow to the extremities and increases the risk for the development of complications such as acute and chronic non-healing wounds and limb loss. NOVADAQ is the exclusive worldwide distributor of LifeNet Health’s DermACELL acellular tissue products for wound and breast reconstruction surgery.
For more information, please contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected]
